חוב כולל של החברה: adctherapeutics.com (ADCT)

ADC Therapeutics (ADCT) generates revenue through the development of targeted oncology treatments using antibody-drug conjugates, including the sale of approved drugs for lymphoma. The company is among the organizations developing advanced technologies to combat blood cancer. This daily price action reflecting the 0.00 metric complements data on Zynlonta sales growth and the preparation of new combination tests.

Fundamental asset screening begins with an assessment of the issuer's financial stability. This indicator aggregates all short-term and long-term liabilities to measure the company's total debt load. By analyzing the volume of debt capital, an investor determines the default risk and the cost of servicing borrowings. For ADC Therapeutics (ADCT), this metric is critical due to the transition toward drug commercialization. High binary risks inherent in biotech make debt control a prerequisite for survival amid unstable sales.